Drug intelligence / Profile preview

PTC-2119

Development stage: Preclinical
Lead developer: Gerotherapeutix
Modality: Small Molecules

Overview

PTC-2119 is a preclinical small molecule candidate developed by Gerotherapeutix for the treatment of mitochondrial rare diseases. It is part of the MitoXcel™ Ouropeptides program, which utilizes MitoXcel™ technology to target and modulate mitochondrial membrane potential (MMP/ΔΨm). The drug is described as having a dual mechanism of action (referred to as Mechanism 1 and 2) aimed at addressing mitochondrial dysfunction and promoting systemic rejuvenation. PTC-2119 is currently being investigated for its potential to treat rare disorders associated with mitochondrial impairment.

Beyond the preview

Go deeper on PTC-2119.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTC-2119.

Explore the full profile